Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026)
On 16 December 2025, the research community was introduced to the JTC2026 during an information day that attracted more than 500 participants. The recording and slides are now available.
With this JTC2026, EP PerMed will fund research projects in human health on innovative Personalised Medicine strategies for patients with cardiovascular, metabolic or kidney diseases. Research projects may focus on a single disease or explore these conditions in combination. Proposals should address one or more of the following aspects:
- Innovative personalised therapeutic approaches;
- Monitoring of treatment response in patients in order to tailor treatment pathways;
- Early disease risk prediction and prevention of disease worsening or comorbidities.
More information about the call and the participating funding organisations are available in the call announcement: https://www.eppermed.eu/funding-projects/calls/jtc2026/
The call will be implemented in two stages, i.e. a pre- and a full proposal phase. The available budget for this call is 38 Mio. € (approx.).
Recording
Agenda
| Time | Topic |
|---|---|
| 10:00 – 10:05 | Dial-in |
| 10:05 – 10:20 | Welcome by the EP PerMed Coordinator EP PerMed coordinator team |
| 10:20 – 11:20 | Introduction in the JTC2026 CARMEN2026 Monika Frenzel (ANR, Joint Call Secretariat) |
| 11:50 – 12:00 | General Questions and Answers |